Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Rick Pauls — FY2025 total compensation $2,727,350

Rick Pauls is President and Chief Executive Officer of DiaMedica Therapeutics Inc. (DMAC). The company reported total compensation of $2,727,350 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$645,000
Bonus$0
Stock awards$0
Option awards$1,652,400
Non-equity incentive plan$412,500
Pension and non-qualified deferred compensation$0
All other compensation$17,450
Total$2,727,350

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure DiaMedica Therapeutics Inc. filed April 1, 2026, accession 0001437749-26-010879.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025President and Chief Executive Officer$645,000$0$0$1,652,400$412,500$0$17,450$2,727,350
FY2024President and Chief Executive Officer$593,250$0$0$633,510$306,975$0$17,250$1,550,985

Totals as disclosed in each year's own compensation disclosure for DiaMedica Therapeutics Inc..

03

Peer context

Peer-group chief executive median$2,149,829
Difference from that median$577,522
Percentile within the disclosed peer group88th
Peers with a disclosed figure8

Medians and percentiles are computed across the peer group DiaMedica Therapeutics Inc. discloses in its own compensation disclosure.

04

The other named executive officers of DiaMedica Therapeutics Inc.

Named executive officerRoleFY2025 total
Rick Pauls this pagePresident and Chief Executive Officer$2,727,350
Julie KropChief Medical Officer$1,707,563
Scott KellenChief Financial Officer and Secretary$1,229,520

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full DiaMedica Therapeutics Inc. compensation brief.

05

The company page

Rick Pauls's compensation sits inside DiaMedica Therapeutics Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The DiaMedica Therapeutics Inc. (DMAC) compensation brief